UBS/CALL/IDORSIA/3.506/0.1666/20.12.24 | Market Closed - Swiss Exchange 16:20:00 04/07/2024 BST | ||
| 0.11 CHF | 0.00% |
|
| 3 months | -45.00% | ||
| 6 months | -26.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IDORSIA LTD
Latest news about IDORSIA LTD
More news
Static data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | IDORSIA LTD |
| Issuer | UBS |
| XIDIDU | |
| ISIN | CH1287911023 |
| Date issued | 25/09/2023 |
| Strike | 3.506 CHF |
| Maturity | 20/12/2024 (168 Days) |
| Parity | 6 : 1 |
| Emission price | 0.17 CHF |
| Emission volume | N/A |
| Settlement | physical |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.24 CHF |
|---|---|
| Lowest since issue | 0.08 CHF |
| Spread | 0.01 CHF |
| Spread % | 8.33% |
Company Profile
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Sector
-
Consensus: Idorsia Ltd
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.14
CHF
Average target price
1.692
CHF
Spread / Average Target
-20.91%
- Stock Market
- Warrants
- XIDIDU Warrant
